WALTHAM, Mass.--(EON: Enhanced Online News)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2017 Conference being held at the Hilton San Francisco Union Square in San Francisco, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell® Wearable Pain Relief Technology™. The presentation is scheduled for Tuesday, January 10, 2017 at 11:30 a.m. Pacific time. A live audio and slide webcast will be available on the investor relations section of the corporate website, www.NeuroMetrix.com. This webcast will be archived after the live event.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
About Biotech Showcase
Biotech Showcase is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.